Publications by authors named "Mark Frattini"

Claim this Profile
A
Antiproliferative Activity of : Overcoming Chemoresistance.
Vladimir Yong-Gonzalez, Constantin Radu, Paul A Calder, David Shum, Mark G Frattini

Comb Chem High Throughput Screen· June 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 study of IDH305 in patients with IDH1-mutant acute myeloid leukemia or myelodysplastic syndrome.
Courtney D DiNardo, Andreas Hochhaus, Mark G Frattini, Karen Yee, Thomas Zander

J Cancer Res Clin Oncol· March 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD123-directed allogeneic chimeric-antigen receptor T-cell therapy (CAR-T) in blastic plasmacytoid dendritic cell neoplasm (BPDCN): Clinicopathological insights.
Naveen Pemmaraju, Nathaniel R Wilson, Jayastu Senapati, Minas P Economides, Monica L Guzman, Mark G Frattini

Leuk Res· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Treatment of Patients with Acute Myeloid Leukemia with the Targeted Alpha-Particle Nanogenerator Actinium-225-Lintuzumab.
Todd L Rosenblat, Michael R McDevitt, Jorge A Carrasquillo, Neeta Pandit-Taskar, Mark G Frattini

Clin Cancer Res· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
Courtney D DiNardo, Andre C Schuh, Eytan M Stein, Pau Montesinos, Andrew H Wei, Mark G Frattini

Lancet Oncol· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improved survival with enasidenib versus standard of care in relapsed/refractory acute myeloid leukemia associated with IDH2 mutations using historical data and propensity score matching analysis.
Stéphane de Botton, Joseph M Brandwein, Andrew H Wei, Arnaud Pigneux, Bruno Quesnel, Mark G Frattini

Cancer Med· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Leukemia stemness and co-occurring mutations drive resistance to IDH inhibitors in acute myeloid leukemia.
Feng Wang, Kiyomi Morita, Courtney D DiNardo, Ken Furudate, Tomoyuki Tanaka, Mark Frattini

Nat Commun· May 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ivosidenib or enasidenib combined with intensive chemotherapy in patients with newly diagnosed AML: a phase 1 study.
Eytan M Stein, Courtney D DiNardo, Amir T Fathi, Alice S Mims, Keith W Pratz, Mark G Frattini

Blood· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A novel differentiation response with combination IDH inhibitor and intensive induction therapy for AML.
Emily F Mason, Olga Pozdnyakova, Mikhail Roshal, Amir T Fathi, Eytan M Stein, Mark Frattini

Blood Adv· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Human DDK rescues stalled forks and counteracts checkpoint inhibition at unfired origins to complete DNA replication.
Mathew J K Jones, Camille Gelot, Stephanie Munk, Amnon Koren, Yoshitaka Kawasoe, Mark G Frattini

Mol Cell· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I Study of Alvocidib Followed by 7+3 (Cytarabine + Daunorubicin) in Newly Diagnosed Acute Myeloid Leukemia.
Joshua F Zeidner, Daniel J Lee, Mark Frattini, Gil D Fine, Judy Costas

Clin Cancer Res· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mutant Isocitrate Dehydrogenase 1 Inhibitor Ivosidenib in Combination With Azacitidine for Newly Diagnosed Acute Myeloid Leukemia.
Courtney D DiNardo, Anthony S Stein, Eytan M Stein, Amir T Fathi, Olga Frankfurt, Mark G Frattini

J Clin Oncol· January 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enasidenib in patients with mutant IDH2 myelodysplastic syndromes: a phase 1 subgroup analysis of the multicentre, AG221-C-001 trial.
Eytan M Stein, Amir T Fathi, Courtney D DiNardo, Daniel A Pollyea, Gail J Roboz, Mark G Frattini

Lancet Haematol· April 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.
Daniel A Pollyea, Martin S Tallman, Stéphane de Botton, Hagop M Kantarjian, Robert Collins, Mark G Frattini

Leukemia· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clonal diversity predicts adverse outcome in chronic lymphocytic leukemia.
Alexander C Leeksma, Justin Taylor, Bian Wu, Jeffrey R Gardner, Jie He, Mark G Frattini

Leukemia· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Isoform Switching as a Mechanism of Acquired Resistance to Mutant Isocitrate Dehydrogenase Inhibition.
James J Harding, Maeve A Lowery, Alan H Shih, Juan M Schvartzman, Shengqi Hou, Mark G Frattini

Cancer Discov· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Deep learning using tumor HLA peptide mass spectrometry datasets improves neoantigen identification.
Brendan Bulik-Sullivan, Jennifer Busby, Christine D Palmer, Matthew J Davis, Tyler Murphy, Mark Frattini

Nat Biotechnol· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
K
Kinase-dead ATR differs from ATR loss by limiting the dynamic exchange of ATR and RPA.
Demis Menolfi, Wenxia Jiang, Brian J Lee, Tatiana Moiseeva, Zhengping Shao, Mark G Frattini

Nat Commun· December 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Micafungin versus posaconazole prophylaxis in acute leukemia or myelodysplastic syndrome: A randomized study.
David J Epstein, Susan K Seo, Yao-Ting Huang, Jay H Park, Virginia M Klimek, Mark G Frattini

J Infect· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure.
Amer M Zeidan, Hanna A Knaus, Tara M Robinson, Andrea M H Towlerton, Edus H Warren, Mark G Frattini

Clin Cancer Res· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
Highly Sensitive Virome Capture Sequencing Technique VirCapSeq-VERT Identifies Partial Noncoding Sequences but no Active Viral Infection in Cutaneous T-Cell Lymphoma.
Mary E Anderson, Dorottya Nagy-Szakal, Komal Jain, Christina C Patrone, Mark G Frattini

J Invest Dermatol· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
Courtney D DiNardo, Keith W Pratz, Anthony Letai, Brian A Jonas, Andrew H Wei, Mark G Frattini

Lancet Oncol· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase 2 trial of a multivalent WT1 peptide vaccine (galinpepimut-S) in acute myeloid leukemia.
Peter G Maslak, Tao Dao, Yvette Bernal, Suzanne M Chanel, Rong Zhang, Mark Frattini

Blood Adv· February 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Geminin inhibits a late step in the formation of human pre-replicative complexes.
Min Wu, Wenyan Lu, Ruth E Santos, Mark G Frattini, Thomas J Kelly

J Biol Chem· October 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia.
Marco L Davila, Isabelle Riviere, Xiuyan Wang, Shirley Bartido, Jae Park, Mark G Frattini

Sci Transl Med· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis